The abstract is read at the publisher; the summary is JClub's.
Isobavachalcone (IBC) targets OTUB1 at His217 to suppress deubiquitinase activity, promoting K48-linked PD-L1 ubiquitination and proteasome-dependent degradation.
- Why it matters: Tumors evade immunity via PD-L1–mediated immunosuppression, yet PD-1/PD-L1 blockade often shows low response rates and acquired resistance.
- What they did: Using small-molecule screening, the study shows IBC increases K48-linked polyubiquitination and PD-L1 degradation, reducing tumor PD-L1 and boosting CD8+ T cell cytotoxicity.
- The result: In PD-L1-deficient tumor models IBC does not further enhance antitumor activity, and IBC plus anti-CTLA-4 yields greater antitumor efficacy, supporting an OTUB1–PD-L1 axis.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.